Get the Stockscreener App
67.25
0.46%
0.31
After Hours:
67.44
0.19
+0.28%
Merus N V stock is traded at $67.25, with a volume of 337.59K.
It is up +0.46% in the last 24 hours and up +22.29% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$66.94
Open:
$66.56
24h Volume:
337.59K
Relative Volume:
0.32
Market Cap:
$5.09B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-17.03
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+5.08%
1M Performance:
+22.29%
6M Performance:
+67.29%
1Y Performance:
+30.38%
1-Day Range:
$66.35
$67.44
1-Week Range:
$62.15
$67.59
52-Week Range:
$33.19
$67.59
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
67.25 | 5.06B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Piper Sandler | Overweight |
| Feb-07-25 | Initiated | Wells Fargo | Overweight |
| Nov-21-24 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Mar-28-24 | Initiated | Truist | Buy |
| Mar-04-24 | Reiterated | Needham | Buy |
| Nov-02-23 | Initiated | Canaccord Genuity | Buy |
| Aug-21-23 | Initiated | TD Cowen | Outperform |
| Aug-02-22 | Initiated | Stifel | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Needham | Buy |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-21 | Initiated | William Blair | Outperform |
| Mar-16-21 | Initiated | SVB Leerink | Outperform |
| Jun-26-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-20-19 | Resumed | Guggenheim | Buy |
| Jun-28-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Resumed | Guggenheim | Buy |
| Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
| Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
| Jun-13-16 | Initiated | Citigroup | Buy |
| Jun-13-16 | Initiated | Guggenheim | Buy |
| Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Merus N.V. Moves Into Bullish Territory Based on MACDJuly 2025 Setups & Low Risk High Win Rate Stock Picks - thegnnews.com
Analysts' Top Picks in Healthcare: Merus, AdaptHealth, and Travere Therapeutics - AInvest
The Bull Case For Merus (MRUS) Could Change Following Surging Revenue and Escalating Losses in Q2 2025 - simplywall.st
Merus NV stock hits all-time high at 67.59 USD By Investing.com - Investing.com South Africa
Merus NV stock hits all-time high at 67.59 USD - Investing.com
How Rising Losses and Strong Cash Reserves at Merus (MRUS) Have Changed Its Investment Story - simplywall.st
Is Merus' (MRUS) Rising Revenue and Widening Losses Changing Its Investment Story? - simplywall.st
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference - The Manila Times
Merus Showcases Revolutionary Cancer Treatment Platform at Major Growth Conference: CEO Presentation Details - Stock Titan
Merus to sustain operations through 2028 with $892 million in cash and equivalents. - AInvest
Merus sees cash runway at least into 2028 - TipRanks
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Merus reports Q2 EPS ($2.23), consensus ($1.15) - TipRanks
Merus (MRUS) Q2 Revenue Falls Short of Expectations, Exciting Cl - GuruFocus
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update - GlobeNewswire
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Merus N.V. Forms Bullish Flag — Upside AheadTop Performing Stock Insights Released Daily - metal.it
Merus Awards Massive $15.7M Stock Options Package to Key New Hires in Oncology Push - Stock Titan
What is Merus N.V. company’s growth strategyInvest confidently with professional guidance - Jammu Links News
Does Merus N.V. stock perform well during market downturnsStrong return on assets - Jammu Links News
What is the risk reward ratio of investing in Merus N.V. stockUnlock superior stock analysis tools - Jammu Links News
How volatile is Merus N.V. stock compared to the marketBuild wealth faster with expert stock picks - Jammu Links News
What institutional investors are buying Merus N.V. stockGet daily updates on promising stocks - Jammu Links News
Should I hold or sell Merus N.V. stock in 2025Get insider insights into market trends - Jammu Links News
What makes Merus N.V. stock price move sharplyConsistent high-yield stocks - Jammu Links News
Is it the right time to buy Merus N.V. stockHigh-yield trading alerts - Jammu Links News
10 Best All-Time High Stocks to Buy According to Analysts - Insider Monkey
Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for HNSCC Treatment - TipRanks
Merus N.V. Flashes Buy Signal on Multi Timeframe ChartWeekly Setup With 3x Return Potential Published - metal.it
Options Data Show Bullish Bias in Merus N.V.Multi-Bagger Potential Stock Forecast Tools Released - metal.it
RSI Crosses Above 30 for Merus N.V. — Reversal in SightShort Term Setup With Predictive Chart Confirmed - metal.it
When is Merus N.V. stock expected to show significant growthStock Market Opportunities For Every Investor - Jammu Links News
Why is Merus N.V. stock attracting strong analyst attentionGrow your portfolio with growth-oriented stocks - Jammu Links News
What are Merus N.V. company’s key revenue driversRapid wealth creation - jammulinksnews.com
Merus NV stock reaches all-time high at 66.44 USD By Investing.com - Investing.com South Africa
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):